Conference Coverage

Study: No increased risk of serious AEs with combined urogyn/gyn onc surgery


 

REPORTING FROM SGS 2018


Case patients were women who underwent planned concurrent procedures at a large tertiary care center from January 2004 to June 2017. Of these women, 77% had stress urinary incontinence, 74% had pelvic organ prolapse (with 55% having stage 3 or 4 prolapse), 71% had prolapse repair – most commonly a native-tissue transvaginal colpopexy – as part of their procedure, and 74% had an anti-incontinence procedure – most commonly a transobturator sling.

The most common final histologic diagnosis was benign disease (in 51% of patients), and uterine cancer was the most common malignancy encountered (36% of patients), Dr. Davidson said, noting that other diagnoses included ovarian and vulvar cancer, in 12% and 1% of cases, respectively.


Most surgeries were minimally invasive abdominal hysterectomies (56%), followed by laparotomies in 32%, minor vaginal surgeries in 6%, laparoscopy without hysterectomy in 5%, and vaginal hysterectomy in 1%.

Controls were matched 2:1 based on surgeon, surgery date and invasiveness (surgical route), and final pathological diagnosis.

Pages

Recommended Reading

VIDEO: How to pick surgical margins with mixed breast lesions
MDedge Hematology and Oncology
VIDEO: Wedge resection offers higher survival for NSCLC
MDedge Hematology and Oncology
Solid organ transplantation contributes significantly to incidence of NHL among children and adolescents
MDedge Hematology and Oncology
Award for best hospital goes to … the Mayo Clinic
MDedge Hematology and Oncology
Low malignant potential tumors of the ovary: A review
MDedge Hematology and Oncology
Robotic-assisted pulmonary lobectomy effective for large tumors
MDedge Hematology and Oncology
Keep PCI patients on aspirin for noncardiac surgery
MDedge Hematology and Oncology
VIDEO: Dabigatran effective for myocardial injury after noncardiac surgery
MDedge Hematology and Oncology
VIDEO: Andexanet alfa effectively reverses factor Xa anticoagulant
MDedge Hematology and Oncology
FDA updates breast implant–associated lymphoma cases, risk
MDedge Hematology and Oncology